Novo Nordisk announced on Wednesday that it is trimming its full-year profit outlook following weaker-than-expected quarterly sales of its popular weight-loss drug,
Shares in Novo Nordisk, maker of the obesity drug Wegovy, fell 1.9% on Tuesday following the publication of a data analysis in
Researchers have specified specific genetic markers that may predict which patients with obesity are most likely to respond strongly to Novo Nordisk’s weight-loss